



21st LEAP Platform Meeting

Avanti Blue Nile Hotel, Bahir Dar, Ethiopia

Thursday, 2 October, 2014

OPEN SESSION – Session 1

08:00-11:15		Chair	Dr Ahmed Mudawi Musa , Institute of Endemic Diseases, University of Khartoum, <i>Sudan</i>
	08:00-08:10	Welcome and Introduction	Prof. Asrat Hailu Mekuria , Addis Ababa University, <i>Ethiopia</i> Dr Ahmed Mudawi Musa , Institute of Endemic Diseases, University of Khartoum, Sudan
	8:10-8:25	Test of cure for Visceral Leishmaniasis	Prof. Hashim Ghalib , University of Lausanne, <i>Switzerland</i>
	8:25-9:05	Computational Approaches in Leishmania Drug Development: The CRACT IT Project	Prof. Paul Kaye , University of York, <i>United Kingdom</i>
	9:05-9:25	DNDi – Empower Strategies for Accessing Quality Assured Visceral Leishmaniasis Medicines from India	Prof Paul Lalvani , Empower School of Health, <i>India</i>
	9:25-10:45	VL Landscape Analysis	WWARN
	10:45:11:15	Discussion	
	Break		
CLOSED SESSION - Session 2			
11:25-1:30		Chair	Prof. Asrat Hailu , Addis Ababa University, <i>Ethiopia</i>
	11:30-11:40	FEXI Study Protocol	Dr Robert Kimutai , DNDi, <i>Kenya</i>
	11:40-11:50	FEXI Sudan Site Report	Dr Ahmed Mudawi Musa , Institute of Endemic Diseases, University of Khartoum, Sudan
	11:50-12:00	FEXI Interim Analysis Report	Mr. Raymond Omollo , DNDi, <i>Kenya</i>
	12:00-12:15	FEXI PK Report	Dr. Thomas Dorlo , Utrecht University, <i>the Netherlands</i>
	12:15-12:25	PHINC PK Modelling Results and preparation of amendment	Severine Blesson , DNDi, <i>Switzerland</i>
	12:25-12:35	PV Statistical Analysis Report	Mr. Raymond Omollo , DNDi,



DNDi

Drugs for Neglected Diseases *initiative*



			Kenya
	12:35-12:45	Miltefosine Allometric PK Study update	Dr Fabiana Alves, DNDi, Switzerland
	12:45-1:30	Discussion	
Lunch			
		Chair	Prof. Joseph Olobo, Makerere University, Uganda
2:30-3:30	2:30-3:30	<ul style="list-style-type: none"> - Africoleish amendment update - Brief update on status of projects <ul style="list-style-type: none"> o WP1: replacing LEAP0211 by Fexinidazole PoC and Miltefosine PK o WP2: HIV-VL pentamidine prophylaxis (preliminary results of the 12 months follow-up analysis) o WP3: progress on HIV-VL 0511, review of timelines - Activities on WP4, capacity building <ul style="list-style-type: none"> o Data Core o PhDs / Masters o GCLP and labs accreditation o Internal QA - Nominees for the Project Advisory Committee (PAC) 	Dr Monique Wasunna, KEMRI/DNDi, Kenya & Dr Fabiana Alves, DNDi, Switzerland
	3:30	Break	
		Chair	Simon Bolo, DNDi, Kenya
3:45-6:45		DNDi Africa Strategic Plan Discussion	Fredrick Ogolla, Institute of Health Management, Strathmore University, Kenya
7:30 Dinner			